| 1 | versus | 52,563 |
| 2 | -dose | 19 |
| 3 | verus | 14 |
| 4 | 316lvm | 4 |
| 5 | -including | 3 |
| 6 | noncompressive | 3 |
| 7 | /sublingual | 2 |
| 8 | poladay | 2 |
| 9 | sibrafiban/ticlopidine | 2 |
| 10 | -20-ethyl-dammara-12,24-diene | 1 |
| 11 | -7,7-dimethyl-5-oxo-3-quinolinecarbonitrile | 1 |
| 12 | -acetyl-d-glucal-derived | 1 |
| 13 | -balanced | 1 |
| 14 | -ha-vd | 1 |
| 15 | .intra-operative | 1 |
| 16 | /last | 1 |
| 17 | /mva | 1 |
| 18 | 1,247,119 | 1 |
| 19 | 10/137 | 1 |
| 20 | 10/hydrochlorothiazide | 1 |
| 21 | 23/137 | 1 |
| 22 | 25.42+/-sd | 1 |
| 23 | 3.1-cav | 1 |
| 24 | 38/259 | 1 |
| 25 | 40/amlodipine | 1 |
| 26 | 41,302 | 1 |
| 27 | 46s=ct | 1 |
| 28 | 47.21 | 1 |
| 29 | 6x109or | 1 |
| 30 | 73/259 | 1 |
| 31 | acetaminophen/intravenous | 1 |
| 32 | am-be | 1 |
| 33 | and/orpioglitazone | 1 |
| 34 | cbtp+the | 1 |
| 35 | cr-and | 1 |
| 36 | days±7.3 | 1 |
| 37 | endpoint-was | 1 |
| 38 | group-146 | 1 |
| 39 | group-aged | 1 |
| 40 | groups.plain | 1 |
| 41 | hd= | 1 |
| 42 | height-from | 1 |
| 43 | iabp-induced | 1 |
| 44 | imidazotetrazine | 1 |
| 45 | intervention/29 | 1 |
| 46 | intervention/facilitated | 1 |
| 47 | isis_base | 1 |
| 48 | leucemies | 1 |
| 49 | meltlet | 1 |
| 50 | mg/kg/every | 1 |
| 51 | ml/m2* | 1 |
| 52 | nifedipine-based | 1 |
| 53 | nm.4 | 1 |
| 54 | once-weekly-only | 1 |
| 55 | patients-and | 1 |
| 56 | placebo+phytosterol | 1 |
| 57 | quinoxalin-2-one | 1 |
| 58 | regimen+ec-mps | 1 |
| 59 | rgyas | 1 |
| 60 | secur™ | 1 |
| 61 | sumatriptan/naproxen/1 | 1 |
| 62 | were-steroid | 1 |
| 63 | zse | 1 |
| 1 | -20-ethyl-dammara-12,24-diene | 1 |
| 2 | -7,7-dimethyl-5-oxo-3-quinolinecarbonitrile | 1 |
| 3 | -acetyl-d-glucal-derived | 1 |
| 4 | -balanced | 1 |
| 5 | -dose | 19 |
| 6 | -ha-vd | 1 |
| 7 | -including | 3 |
| 8 | .intra-operative | 1 |
| 9 | /last | 1 |
| 10 | /mva | 1 |
| 11 | /sublingual | 2 |
| 12 | 1,247,119 | 1 |
| 13 | 10/137 | 1 |
| 14 | 10/hydrochlorothiazide | 1 |
| 15 | 23/137 | 1 |
| 16 | 25.42+/-sd | 1 |
| 17 | 3.1-cav | 1 |
| 18 | 316lvm | 4 |
| 19 | 38/259 | 1 |
| 20 | 40/amlodipine | 1 |
| 21 | 41,302 | 1 |
| 22 | 46s=ct | 1 |
| 23 | 47.21 | 1 |
| 24 | 6x109or | 1 |
| 25 | 73/259 | 1 |
| 26 | acetaminophen/intravenous | 1 |
| 27 | am-be | 1 |
| 28 | and/orpioglitazone | 1 |
| 29 | cbtp+the | 1 |
| 30 | cr-and | 1 |
| 31 | days±7.3 | 1 |
| 32 | endpoint-was | 1 |
| 33 | group-146 | 1 |
| 34 | group-aged | 1 |
| 35 | groups.plain | 1 |
| 36 | hd= | 1 |
| 37 | height-from | 1 |
| 38 | iabp-induced | 1 |
| 39 | imidazotetrazine | 1 |
| 40 | intervention/29 | 1 |
| 41 | intervention/facilitated | 1 |
| 42 | isis_base | 1 |
| 43 | leucemies | 1 |
| 44 | meltlet | 1 |
| 45 | mg/kg/every | 1 |
| 46 | ml/m2* | 1 |
| 47 | nifedipine-based | 1 |
| 48 | nm.4 | 1 |
| 49 | noncompressive | 3 |
| 50 | once-weekly-only | 1 |
| 51 | patients-and | 1 |
| 52 | placebo+phytosterol | 1 |
| 53 | poladay | 2 |
| 54 | quinoxalin-2-one | 1 |
| 55 | regimen+ec-mps | 1 |
| 56 | rgyas | 1 |
| 57 | secur™ | 1 |
| 58 | sibrafiban/ticlopidine | 2 |
| 59 | sumatriptan/naproxen/1 | 1 |
| 60 | versus | 52,563 |
| 61 | verus | 14 |
| 62 | were-steroid | 1 |
| 63 | zse | 1 |
| 1 | ml/m2* | 1 |
| 2 | sumatriptan/naproxen/1 | 1 |
| 3 | 47.21 | 1 |
| 4 | 41,302 | 1 |
| 5 | days±7.3 | 1 |
| 6 | nm.4 | 1 |
| 7 | group-146 | 1 |
| 8 | 10/137 | 1 |
| 9 | 23/137 | 1 |
| 10 | 1,247,119 | 1 |
| 11 | intervention/29 | 1 |
| 12 | 73/259 | 1 |
| 13 | 38/259 | 1 |
| 14 | hd= | 1 |
| 15 | /mva | 1 |
| 16 | -balanced | 1 |
| 17 | iabp-induced | 1 |
| 18 | group-aged | 1 |
| 19 | nifedipine-based | 1 |
| 20 | intervention/facilitated | 1 |
| 21 | -acetyl-d-glucal-derived | 1 |
| 22 | were-steroid | 1 |
| 23 | cr-and | 1 |
| 24 | patients-and | 1 |
| 25 | 25.42+/-sd | 1 |
| 26 | -ha-vd | 1 |
| 27 | am-be | 1 |
| 28 | 10/hydrochlorothiazide | 1 |
| 29 | cbtp+the | 1 |
| 30 | -7,7-dimethyl-5-oxo-3-quinolinecarbonitrile | 1 |
| 31 | -20-ethyl-dammara-12,24-diene | 1 |
| 32 | sibrafiban/ticlopidine | 2 |
| 33 | 40/amlodipine | 1 |
| 34 | imidazotetrazine | 1 |
| 35 | quinoxalin-2-one | 1 |
| 36 | and/orpioglitazone | 1 |
| 37 | isis_base | 1 |
| 38 | -dose | 19 |
| 39 | zse | 1 |
| 40 | noncompressive | 3 |
| 41 | .intra-operative | 1 |
| 42 | -including | 3 |
| 43 | /sublingual | 2 |
| 44 | placebo+phytosterol | 1 |
| 45 | height-from | 1 |
| 46 | 316lvm | 4 |
| 47 | groups.plain | 1 |
| 48 | 6x109or | 1 |
| 49 | endpoint-was | 1 |
| 50 | rgyas | 1 |
| 51 | leucemies | 1 |
| 52 | regimen+ec-mps | 1 |
| 53 | acetaminophen/intravenous | 1 |
| 54 | verus | 14 |
| 55 | versus | 52,563 |
| 56 | 46s=ct | 1 |
| 57 | meltlet | 1 |
| 58 | /last | 1 |
| 59 | 3.1-cav | 1 |
| 60 | poladay | 2 |
| 61 | once-weekly-only | 1 |
| 62 | mg/kg/every | 1 |
| 63 | secur™ | 1 |